This medicine is used for managing specific types of Non-Small Cell Lung Cancer (NSCLC). It is commonly used across conditions presenting with early-stage NSCLC; advanced or metastatic NSCLC with specific EGFR activating mutations; and in specific contexts where progression is linked to the T790M mutation.

Quick Fact: Relief for Symptoms related to Advanced Cancer Progression

This treatment is used in situations involving certain distressing symptoms. In the adjuvant setting, this supportive treatment is applied in conditions involving early-stage tumors. The primary benefit for patients may support addressing the continued risk of disease recurrence, which may assist in easing the overall burden of associated symptoms like cough or fatigue. It is relevant in situations involving metastatic NSCLC. This provides therapeutic support that may assist in maintaining stability in the disease manifestations, which helps to ease the overall symptom load of established malignancy.

“This therapy assists with maintaining functional stability and supports general well-being during symptomatic phases.”

This medication may be part of symptomatic management when disease manifestations affect the Central Nervous System (CNS). This approach is relevant in contexts involving heightened systemic burden and contributes to improved comfort by addressing neurological symptoms, supporting the patient’s overall stability during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Тагриссо — Official Regulatory Information

The following rules define the population eligibility for Tagrisso (Osimertinib) based strictly on government regulatory documents.

Category	Regulatory Statement
Populations for whom use is allowed	Adult patients (aged 18 and over) with tumors confirmed to have specific EGFR mutations (e.g., Exon 19 deletions, L858R, or T790M).
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance or any of its formulation ingredients.
Age-related eligibility rules	Use is not established in the pediatric population (under 18 years). Use is established in older adults (65 years).
Condition-specific eligibility rules	Use is not recommended for patients with Severe Hepatic Impairment (Child-Pugh C) due to insufficient data. End-Stage Renal Disease or use with dialysis is classified as Use Not Established.
Pregnancy and lactation eligibility status	Pregnancy: Not recommended; the drug can cause embryo-fetal toxicity. Lactation: Do not breastfeed during treatment and for a specific period after the final dose.
Eligibility-related restrictions	Use is conditional for patients with cardiac risk factors (e.g., history of QTc prolongation), requiring mandatory monitoring (ECG/LVEF assessment). Females and males of reproductive potential must use effective contraception for specified durations.

Interactions with Other Medicines and Products

Tagrisso (Osimertinib) interactions are primarily related to its metabolism via the CYP3A4 enzyme system and its activity as an inhibitor of drug transporters.

Pharmacokinetic Interactions

Interaction Type	Interacting Substance/Class	Regulatory Recommendation
Decreased Osimertinib Exposure	Strong CYP3A4 Inducers (e.g., Rifampin, St. John's Wort)	Concomitant use with strong inducers must be avoided (St. John's Wort is contraindicated) as this significantly reduces the concentration of Tagrisso.
Increased Co-administered Drug Exposure	P-glycoprotein ( P-gp) and BCRP Substrates (e.g., Rosuvastatin, Fexofenadine)	Osimertinib inhibits these transporters, leading to increased levels of the co-administered drug. Monitoring for adverse reactions of the substrate drug is advised.
No Significant Interaction	Strong CYP3A4 Inhibitors (e.g., Itraconazole) or Gastric Acid Reducing Agents (e.g., Omeprazole)	No clinically significant change in Osimertinib exposure is expected; no dose adjustments are typically required.

Pharmacodynamic Interactions

Osimertinib can prolong the QTc interval. Combining Tagrisso with other medicines known to cause QTc prolongation should be undertaken with caution and may require periodic ECG and electrolyte monitoring, especially in patients with predisposing cardiac conditions. The antibiotic Lefamulin is contraindicated due to its QTc prolongation risk and CYP3A4 substrate property.

How Тагриссо Works: Mechanism of Action

---

Targeting Mutated EGFR and Blocking Signal Initiation

This medication functions as an irreversible inhibitor by forming a permanent, covalent bond with specific mutated forms of the Epidermal Growth Factor Receptor (EGFR) protein, including the T790M resistance mutation. This interaction irreversibly inhibits the function of the mutated receptor, initiating the modulation of the signaling cascade associated with cellular proliferation.

---

Interrupting Pro-Survival Signaling Cascades

Inhibiting the receptor prevents it from activating downstream growth and survival signals through the cell's internal machinery, such as the PI3K/AKT and MEK/ERK pathways. This interruption of the pro-survival signals leads to a fundamental physiological effect where the targeted cells undergo regulated cell death (apoptosis) and exhibit a reduced proliferation rate.

---

Mechanistic Action in Central Tissues

Additionally, the drug possesses the necessary lipophilic property to pass across the blood-brain barrier (BBB) and penetrate the central nervous system (CNS). This distribution property allows the signal-blocking mechanism to be active in target cells located in both central and peripheral tissues, leading to reduced proliferation and survival signals across these compartments.

How Tagrisso (Osimertinib) is Used

Tagrisso is administered via the oral route as a film-coated tablet, ensuring systemic delivery of the active substance, Osimertinib. The medicine is taken once daily, establishing a consistent treatment pattern. The standard starting dose for all approved adult indications is 80 mg.

---

Administration Requirements

Usage Condition	Instruction
Route & Form	Oral; swallowed whole. The tablet must not be crushed, split, or chewed.
Food Relationship	Can be taken with or without food.
Preparation	For patients unable to swallow solids, the tablet can be dispersed in non-carbonated water only (e.g., 60 mL), and the resulting liquid must be consumed immediately.

---

Dose and Duration Protocols

Duration of Use

The treatment period is determined by the specific clinical context. In the adjuvant setting, the administration is continued for a maximum of three years or until disease recurrence or unacceptable toxicity. In the metastatic or locally advanced setting, treatment continues until disease progression or unacceptable toxicity.

Dose Adjustments

The standard daily dose is subject to modification based on specific circumstances. The dose may be reduced to 40 mg once daily to manage certain adverse reactions. Conversely, the dose is increased to 160 mg once daily when the drug is co-administered with a strong CYP3A enzyme inducer.

Handling a Missed Dose

If a dose is missed, it is generally advised not to take the missed dose if the next dose is due soon; instead, the patient should continue with the next scheduled dose at the usual time.

Research Evidence / Overview of Studies for Osimertinib

Evidence for use in Adjuvant Treatment for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Studies were conducted using Osimertinib following surgery for early-stage NSCLC that carries the EGFR gene mutation. These efforts primarily involved randomized controlled trials (RCTs), where patients who had their tumor completely removed were monitored over defined time intervals. Studies reported patterns where the observed rate of cancer recurrence was lower than the observed rate for those receiving placebo. The results apply only to the populations studied in these clinical trials. What remains uncertain is the full long-term impact, as follow-up durations were limited.

Evidence for use in Locally Advanced or Metastatic NSCLC (First-Line Setting)

Osimertinib was evaluated in studies as a starting treatment for individuals whose NSCLC was locally advanced or metastatic and carried the EGFR mutation. The research examined outcomes reflecting daily functioning and overall disease progression. Findings indicate patterns related to progression-free survival, and these studies report how symptoms evolved in the observed populations. Comparative evidence between Osimertinib alone and Osimertinib combined with chemotherapy is still emerging.

Evidence for use in Previously Treated Metastatic NSCLC

Osimertinib was studied for patients whose cancer developed the specific T790M resistance mutation following prior TKI treatment. Imaging scans measured a reduction in tumor size in a portion of the studied population. Sample sizes in some initial studies were modest, and evidence quality varies across studies. Data for certain groups, such as those with brain metastases, remain insufficient.

What is Still Uncertain About Osimertinib

Limitations remain in the research regarding real-world experience, the full scope of long-term effects reported, and patient-reported outcomes. Comparative evidence is lacking for certain treatment sequences, and data are still emerging on management strategies once the cancer develops resistance. Evidence highlights what is known—and what is still uncertain—and provides context but not individual predictions.

Common questions about Тагриссо (FAQ)

Q: How quickly does Тагриссо typically start working?

Official regulatory studies do not specify a fixed timeline for the drug to start controlling the disease. Clinical trials measure effectiveness by monitoring specific metrics, such as objective response rate (tumor shrinkage) and progression-free survival, which track disease control over a period of weeks to months.

Q: Is it normal to feel more tired than usual when starting Тагриссо?

Yes, fatigue is documented in the official product information as one of the most frequently reported side effects. It is classified as a very common adverse reaction in clinical trials, as it was experienced by a significant number of patients.

Q: Are there any specific foods or drinks to avoid while on Тагриссо?

Official regulatory information specifies that the herbal preparation St. John's Wort must be avoided. St. John's Wort is contraindicated because it can significantly reduce the concentration of Тагриссо in the body.

Q: Can Тагриссо be taken with blood pressure medication?

Regulatory guidance advises caution when combining this medicine with any drug known to prolong the QTc interval. This is because combining these medicines may increase the risk of a serious heart rhythm change (QTc prolongation). Periodic monitoring may be required.

Q: What should I do if I miss a dose of Тагриссо?

If a dose is missed, official regulatory guidance indicates continuing with the next scheduled dose at the usual time. It advises against taking the missed dose if the next one is due soon.

Q: Are there any long-term side effects associated with Тагриссо use?

The official product labeling focuses on adverse reactions observed during clinical trials. Regulatory information highlights the potential for serious reactions, such as Cardiomyopathy (heart muscle disease) and Interstitial Lung Disease (ILD), which are serious and may require clinical management.

Q: Are there any known interactions between Тагриссо and herbal supplements?

Yes, official regulatory documents explicitly state that the herbal supplement St. John's Wort is contraindicated, and regulatory documents advise avoiding its use. It is classified as a strong enzyme inducer that significantly lowers the amount of Тагриссо in the bloodstream.

Q: Can I take multivitamins while undergoing treatment with Тагриссо?

Regulatory documents do not specifically list multivitamins as an interacting substance. The primary known drug interactions involve strong enzyme inducers and certain drug transporters.

Q: Does Тагриссо cause changes in eyesight or vision?

Yes. The official prescribing information notes that the medicine has been associated with Keratitis (inflammation of the cornea). If vision changes occur, they should be reported to a healthcare provider.

Q: How often do patients typically need check-ups while taking Тагриссо?

Official regulatory documents do not specify a universal check-up schedule. However, they require periodic monitoring of certain health indicators, such as heart function and blood cell counts, throughout the treatment period.

Q: Is there a generic version of Тагриссо available?

Тагриссо is the brand name for the active ingredient osimertinib. According to official regulatory records, a generic version of osimertinib is currently not approved for use in the United States.

Q: What are the serious but less common side effects of Тагриссо?

Serious adverse reactions highlighted in official product information include Interstitial Lung Disease (ILD)/Pneumonitis, Cardiomyopathy (heart failure), and severe skin reactions like Stevens-Johnson Syndrome (SJS). These are serious but occur with lower frequency than the very common side effects.

Q: Will taking Тагриссо affect my ability to drive or operate machinery?

The European regulatory documentation states that this medicine has no or negligible influence on the ability to drive and use machines.

Q: What is the success rate of Тагриссо in clinical trials?

Regulatory data reports clinical outcomes using specific measures, such as the Objective Response Rate (ORR), which indicates how often tumors shrink, and Progression-Free Survival (PFS). Clinical outcomes vary, depending on the specific type and stage of lung cancer studied.

Q: Can people with heart conditions safely take Тагриссо?

The official label notes that the drug carries warnings related to the heart, including the risk of QTc prolongation and Cardiomyopathy. Patients with certain cardiac risk factors may require periodic heart monitoring before and during treatment, as noted in the official prescribing information.

Q: Does Тагриссо have an impact on a patient's immune system?

The drug is associated with hematologic changes, including decreases in certain white blood cells (lymphopenia and leukopenia), which are classified as very common adverse reactions.

Q: Can Тагриссо be used during the initial stages of lung cancer?

Yes. Тагриссо is approved as adjuvant treatment (given after surgery) for certain adult patients with early-stage (specifically, Stage IB, II, and IIIA) Non-Small Cell Lung Cancer (NSCLC) who have specific EGFR mutations.

Q: Can Тагриссо be taken with medications for high cholesterol?

Тагриссо inhibits certain drug transporters. Taking it with some cholesterol-lowering medicines, such as Rosuvastatin, may increase the concentration of the cholesterol drug in the body. Regulatory information notes that monitoring for adverse reactions of the co-administered drug may be necessary.

How to Store and Dispose of Tagrisso (Osimertinib)

Tagrisso tablets must be stored according to specific regulatory requirements to maintain product stability and safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at Controlled Room Temperature, which is 25 C (77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F).
Packaging	Must be stored in the original container at all times.
Safety	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Tagrisso must be disposed of in accordance with local requirements for pharmaceutical waste. The medicine must not be disposed of via wastewater or household waste to protect the environment.